Compare Johnson & Johnson (JNJ) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs KLA Corp. — how do they compare? Johnson & Johnson trades at $260.76 (market cap $626.09B), while KLA Corp. trades at $209.09 (market cap $261.92B). The key difference: Johnson & Johnson is far larger — about 2.4× KLA Corp.'s market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| JNJ | KLAC | |
|---|---|---|
Market Cap | $626.09B | $261.92B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $301.71 |
52-Week Low | $172.78 | $84.39 |
Enterprise Value | $654.37B | $263.17B |
Dividend Yield | 2.06% | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
KLA Corporation (KLAC) trades at $209.16, up 8.52% over 24 hours, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock exhibits robust fundamentals with a 35.57% net income margin and 87.5% ROE, supported by a recent dividend hike and stock split. Analyst consensus is bullish with a $246.93 price target, though elevated valuation ratios like a P/E of 54.77 warrant caution.
Outlook remains positive driven by AI-driven semiconductor equipment demand, but risks include high valuation sensitivity and cyclical industry exposure. The stock offers growth potential with disciplined risk management advised given overbought technical conditions and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
